Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Theratechnologies Trading Down 1.3 %
THTX Stock traded down $0.03 during mid-day trading on Wednesday, hitting $2.20. 135,270 shares of the company were exchanged, compared to its average volume of 65,366. The company has a quick ratio of 1.07, a current ratio of 1.57 and a debt-to-equity ratio of 5.38. The firm has a market capitalization of $209.27 million, a P/E ratio of -4.17 and a beta of 1.32. The business has a fifty day simple moving average of $2.29 and a 200-day simple moving average of $2.53. Theratechnologies has a 12-month low of $1.90 and a 12-month high of $4.46.
Theratechnologies (NASDAQ:THTX - Get Rating) last issued its quarterly earnings results on Thursday, July 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. The business had revenue of $19.27 million for the quarter. Theratechnologies had a negative return on equity of 474.37% and a negative net margin of 68.75%. On average, equities research analysts predict that Theratechnologies will post -0.38 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, National Bank Financial lowered their target price on shares of Theratechnologies from C$3.75 to C$3.25 in a research note on Friday, July 15th.